# List of Tables

<table>
<thead>
<tr>
<th>Table No.</th>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Novel targets and treatments available for the Type 2 diabetes mellitus</td>
<td>2</td>
</tr>
<tr>
<td>1.2</td>
<td>Advantages and limitations of DPP-4 inhibitors</td>
<td>7</td>
</tr>
<tr>
<td>1.3</td>
<td>Pharmacodynamics and pharmacokinetics of marketed DPP-4 inhibitors</td>
<td>9</td>
</tr>
<tr>
<td>1.4</td>
<td>Selectivity of marketed drugs against various DPP enzymes</td>
<td>11</td>
</tr>
<tr>
<td>2.1</td>
<td>Various heterocyclic scaffolds reported for DPP-4 inhibition.</td>
<td>21</td>
</tr>
<tr>
<td>3.1</td>
<td>Structures of quinoline/isoquinoline analogues as DPP-4 inhibitors with their actual activity</td>
<td>46</td>
</tr>
<tr>
<td>3.2</td>
<td>Statistical results of CoMFA and CoMSIA models by PLS analysis based on three different alignments</td>
<td>52</td>
</tr>
<tr>
<td>3.3</td>
<td>Actual pIC$<em>{50}$, CoMFA/CoMSIA-predicted pIC$</em>{50}$ and residual values of molecules in training and test sets</td>
<td>53</td>
</tr>
<tr>
<td>3.4</td>
<td>Analyses of critical amino acids for DPP-4 inhibition from 41 co-crystal structures deposited in protein data bank</td>
<td>61</td>
</tr>
<tr>
<td>3.5</td>
<td>Results of the Hip-Hop run of pharmacophore modelling</td>
<td>67</td>
</tr>
<tr>
<td>3.6</td>
<td>Validation results based on ROC curve analysis for generated pharmacophore models.</td>
<td>70</td>
</tr>
<tr>
<td>3.7</td>
<td>Validation results based on the Guner-Henry scoring method for generated pharmacophore models</td>
<td>71</td>
</tr>
<tr>
<td>3.8</td>
<td>Pharmacophore mapping of the marketed drugs</td>
<td>72</td>
</tr>
<tr>
<td>3.9</td>
<td>The best <em>in-silico</em> hits with their docking scores</td>
<td>75</td>
</tr>
<tr>
<td>3.10</td>
<td>Designed molecules with their pharmacophore mapping and docking results</td>
<td>81</td>
</tr>
<tr>
<td>3.11</td>
<td><em>In-silico</em> ADMET properties of designed molecules</td>
<td>85</td>
</tr>
<tr>
<td>4.2</td>
<td>Single crystal XRD parameters of compound 5p</td>
<td>119</td>
</tr>
<tr>
<td>4.3</td>
<td>Results of the purity of compounds by HPLC analysis</td>
<td>120</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>4.4</td>
<td>Actual (experimental) and predicted logP values of synthesized molecules</td>
<td>136</td>
</tr>
<tr>
<td>5.1</td>
<td><em>In-vitro</em> screening of molecules for DPP-4 inhibition</td>
<td>141</td>
</tr>
<tr>
<td>5.2</td>
<td>% DPP-4 inhibition by compounds 5q and 5c</td>
<td>143</td>
</tr>
<tr>
<td>5.3</td>
<td>% DPP-8 and % DPP-9 inhibition by compound 5q and 5c</td>
<td>144</td>
</tr>
</tbody>
</table>